HMGB1 and metabolic dysfunction-associated steatotic liver disease: Therefore, we hypothesized that SIRT1 may suppress HMGB1 release in high-fat diet (HFD)-induced NAFLD, thereby affording a novel target for anti-inflammatory therapy for NAFLD.